About this episode
In this Mini Mikkipedia episode, Mikki breaks down the rapidly growing world of obesity pharmacotherapy, focusing on GLP-1 receptor agonists like semaglutide and the newer dual GLP-1/GIP drugs such as tirzepatide. With more people beginning these medications, understanding how they work—and how to use them effectively—has never been more important. Mikki explains the biology behind appetite regulation, the clinical trial data showing significant weight loss, and why these drugs are best viewed as long-term treatments rather than short courses. The episode also dives into the practical realities many people face once they start therapy: managing common gastrointestinal side effects, protecting muscle and bone during weight loss, and setting realistic expectations about outcomes. Whether you’re considering these medications yourself or supporting someone who is, this episode provides a clear, science-based guide to navigating the experience.Highlights:How GLP-1 and GLP-1/GIP medications regulate appetite and metabolismClinical trial results: expected weight loss with semaglutide vs tirzepatideWhy weight regain often occurs after stopping the drugsPractical strategies to manage nausea, constipation, and other GI side effectsProtecting muscle and bone with protein intake and resistance training
Contact Mikki:https://mikkiwilliden.com/https://www.facebook.com/mikkiwillidennutritionhttps://www.instagram.com/mikkiwilliden/https://linktr.ee/mikkiwillidenNZ listeners - save 10% off Calocurb by using the code Mikkipedia10 at www.calocurb.co.nzSave 20% on all Nuzest Products WORLDWIDE with the code MIKKI at www.nuzest.co.nz, www.nuzest.com.au or www.nuzest.comCurranz supplement: MIKKI saves you 25% at www.curranz.co.nz or www.curranz.co.uk off your first order
